Minerva Neurosciences (NASDAQ:NERV) Upgraded to “Hold” by StockNews.com

StockNews.com upgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a sell rating to a hold rating in a report published on Thursday.

Separately, HC Wainwright decreased their price target on Minerva Neurosciences from $11.00 to $7.00 and set a neutral rating for the company in a report on Thursday.

Minerva Neurosciences Trading Up 0.9 %

NASDAQ NERV traded up $0.02 during trading on Thursday, reaching $2.37. The company’s stock had a trading volume of 15,458 shares, compared to its average volume of 17,188. Minerva Neurosciences has a twelve month low of $2.29 and a twelve month high of $13.49. The business’s fifty day moving average price is $2.66 and its 200-day moving average price is $5.30.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.31). Analysts expect that Minerva Neurosciences will post -3.57 earnings per share for the current year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.